Cardiac usage of reducible poly(oligo-D-arginine) as a gene carrier for vascular endothelial growth factor expression

Jongsu Woo, Seong Ho Bae, Bokyoung Kim, Jin Sil Park, Subin Jung, Minhyung Lee, Yong Hee Kim, Donghoon Choi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Developments of non-viral carriers have headed toward reducing cytotoxicity, which results from the use of conventional gene carriers, and enhancing gene delivery efficiency. Cys- (D-R9)-Cys repeated reducible poly(oligo-D-arginine) (rPOA) is one of the most efficient non-viral carriers for gene therapy; however, while its efficiency has been verified in the lung and brain, it is necessary to confirm its activity in each organ or tissue since there are differences of gene carrier susceptibility to among tissue types.We therefore tested the compatibility of rPOA in cardiac tissue by in vitro or in vivo experiments and confirmed its high transfection efficiency and low cytotoxicity. Moreover, substantial regenerative effects were observed following transfection with rPOA/pVEGF expression vector complexes (79% decreased infarct size) compared to polyethyleneimine (PEI) (34% decreased infarct size) in a rat myocardial infarction (MI) model. These findings suggest that rPOA efficiently enables DNA transfection in cardiac tissue and can be used as a useful non-viral therapeutic gene carrier for gene therapy in ischemic heart disease.

Original languageEnglish
Article numbere0144491
JournalPloS one
Volume10
Issue number12
DOIs
Publication statusPublished - 2015 Dec 1

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'Cardiac usage of reducible poly(oligo-D-arginine) as a gene carrier for vascular endothelial growth factor expression'. Together they form a unique fingerprint.

  • Cite this